Various proposals on drug resistance (AMR)
At a time when there was growing recognition of the need for a global approach to tackling drug resistance (AMR) that transcends the boundaries between humans, animals, and the environment, the World Health Organization (WHO) highlighted drug resistance on World Health Day in 2011 and called for the promotion of a global approach based on a one-health approach. In 2013, the G8 Science Council, a collection of scientific councils from the Group of Eight (G8) countries, issued a joint statement on the threat of drug resistance, and in 2014, the World Health Organization (WHO) released the first-ever global trends report on the current state of drug resistance. In May 2015, the World Health Assembly adopted the Global Action Plan on Drug Resistance (AMR), calling on member countries to develop their own action plans within two years.
In addition, at the June 2015 Elmau Summit of the Group of Seven (G7) developed countries of Germany, drug resistance was addressed as one of the main issues and the formulation of the WHO Global Action Plan was welcomed, while the need to strengthen the One Health Approach and research and development of new drugs and other technologies was discussed. In 2016, Japan assumed the G7 Presidency and, in addition to the agenda of the Elmau Summit, promoted international cooperation to maintain the efficacy of antimicrobial agents as an international public good, including the establishment of surveillance systems and promotion of appropriate use of antimicrobial agents to combat AMR. 2017 G20 Hamburg Summit The Global AMR R&D Hub was launched in Germany in May 2018, based on the Leaders' Declaration, which agreed to establish an international drug resistance R&D hub as a new international framework.
JPMA's Recommendations on AMR
The Japanese Pharmaceutical Manufacturers Association (JPMA) and the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) jointly submitted the "Proposals from the Pharmaceutical Industry for the G7 Hiroshima Summit Health Agenda" to the Prime Minister, Minister of Health, Labor and Welfare, Minister of Finance, and Minister of Foreign Affairs.
In 2016, the JPMA continued to review the results of the One Health Approach, particularly the promotion of appropriate use through the establishment and strengthening of a surveillance system for drug-resistant bacteria, i.e., the early realization of antimicrobial stewardship, as well as the promotion of immunization, which is extremely effective as a long-term countermeasure against infectious diseases. In addition to the promotion of early realization of antimicrobial stewardship, we requested the Japanese government to take the lead in global efforts for immunization, which is extremely effective as a long-term countermeasure against infectious diseases, before the G7 Ise-Shima Summit and the G7 Kobe Health Ministers Meeting.
In April 2017, we submitted a proposal to the MHLW on measures to promote research and development to combat AMR.
In June 2019, we submitted a proposal from the pharmaceutical industry to the Minister of Health, Labour and Welfare regarding the introduction of pull-type incentives to promote research and development of medicines and other products against drug resistance (AMR). The same proposal was also submitted to the Director-General of the Medical Affairs Bureau, the Director-General of the Health Bureau, the Director-General of the Pharmaceuticals and Lifestyle Health Bureau, the Director-General of the Insurance Bureau, and the Director of the Health Sciences Division of the Ministry of Health, Labour and Welfare.
In January 2019, " Recommendations from the pharmaceutical industry for the G20 Osaka Summit Health Agenda:" was submitted to the Prime Minister, the Minister of Health, Labor and Welfare, the Minister of Finance, and the Minister of Foreign Affairs.
- Recommendations from the pharmaceutical industry for the G20 Osaka Summit Health Agenda: （Proposal to the Prime Minister (233KB)
- Recommendations from the pharmaceutical industry for the G20 Osaka Summit Health Agenda: (To the Minister of Health, Labour and Welfare) (232KB)
- Recommendations from the pharmaceutical industry for the G20 Osaka Summit Health Agenda: (To the Minister of Finance) (232KB)
- Recommendations from the pharmaceutical industry for the G20 Osaka Summit Health Agenda: （To the Minister of Foreign Affairs (233KB)
In October 2019, " Recommendations from Pharmaceutical Industry for G20 Health Ministers Meeting:" was submitted to the Minister of Health, Labour and Welfare.
Joint IFPMA-JPMA-PhRMA Letter for G20 Japan-Saudi transition: " jointly with the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) and the Pharmaceutical Research and Manufacturers of America (PhRMA) was submitted to the Minister of Foreign Affairs and the Minister of Health of Saudi Arabia, which will host the G20 next year, and Japan, which will host the G20 this year.